12b80-hbp

Atlanthera is pleased to announce the beginning of the clinical veterinary phase for its lead compound 12b80 targetting bone tumors. After successfull proof of concept phase, especially on rodent, 12b80 12b80 is confirmed as a potent anti-cancer molecule.
See more on 12b80 >